Literature DB >> 1938516

Radiotherapy in T1 laryngeal cancer: prognostic factors for locoregional control and survival, uni- and multivariate analysis.

C H Terhaard1, K Snippe, L A Ravasz, I van der Tweel, G J Hordijk.   

Abstract

From 1975 through 1985, 194 patients with T1 glottic, 37 patients with T1 supraglottic, and 3 patients with T1 subglottic cancer were treated with radiotherapy. Local control and ultimate locoregional control (after salvage surgery) was 91% and 97% for T1 glottic, 84% and 81% for T1 supraglottic, and 2/3 and 3/3, respectively for subglottic tumors. In uni- and multivariate analysis local control for glottic tumors was associated with extension of the tumor on the vocal cord (entire length of vocal cord vs others, p = 0.01) and continuation of smoking after therapy (yes/no, p = 0.03). No prognostic factor for local control was found in supraglottic tumors. However, regional control and survival were impaired by N stage (N0 vs N+, p less than 0.0005), local recurrence (yes/no, p less than 0.0005), and extension of the tumor (one supraglottic subsite vs more than one, p less than 0.05). Mild late complications were seen in 13% of patients without salvage therapy. Following univariate analysis, field size, fraction size (greater than 2 Gy), maximum tumor dose (greater than 70 Gy), age, post-treatment biopsy, and tumor site were associated with complication rate. Following multivariate analysis, site, fraction size, maximum tumor dose, and continuation of smoking after therapy were independent prognostic factors for mild late complications (mostly arytenoid edema).

Entities:  

Mesh:

Year:  1991        PMID: 1938516     DOI: 10.1016/0360-3016(91)90274-8

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Outcome of radiotherapy in T1 glottic carcinoma: a population-based study.

Authors:  Elisabeth Victoria Sjögren; Ruud G J Wiggenraad; Saskia Le Cessie; Simone Snijder; Jaqueline Pomp; Robert Jan Baatenburg de Jong
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-10-07       Impact factor: 2.503

2.  [Reasons for the terms "radiosurgery" and "Gamma Knife"].

Authors:  K Hamm; G Surber
Journal:  HNO       Date:  2017-09       Impact factor: 1.284

3.  Radiotherapy for T1a glottic cancer: the influence of smoking cessation and fractionation schedule of radiotherapy.

Authors:  Abrahim Al-Mamgani; Peter H van Rooij; Robert Mehilal; Gerda M Verduijn; Lisa Tans; Stefan L S Kwa
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-06-25       Impact factor: 2.503

4.  High-dose radiotherapy alone for patients with T4-stage laryngeal cancer.

Authors:  A Mucha-Małecka; K Składowski
Journal:  Strahlenther Onkol       Date:  2013-07-05       Impact factor: 3.621

Review 5.  Systematic Review of Tobacco Use after Lung or Head/Neck Cancer Diagnosis: Results and Recommendations for Future Research.

Authors:  Jessica L Burris; Jamie L Studts; Antonio P DeRosa; Jamie S Ostroff
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-08-17       Impact factor: 4.254

6.  The "gregorio marañon" hospital experience in the treatment of laryngeal carcinoma.

Authors:  M F Vega; T Martinez; B Scola; E Scola; S F Vega
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  1997-07

7.  Treatment of T3 laryngeal cancer in the Netherlands: a national survey.

Authors:  Patricia Doornaert; Chris H J Terhaard; Johannes H Kaanders
Journal:  Radiat Oncol       Date:  2015-06-26       Impact factor: 3.481

8.  Concurrent chemoradiotherapy with conventional fractionated radiotherapy and low-dose daily cisplatin plus weekly docetaxel for T2N0 glottic cancer.

Authors:  Jun-Ichi Saitoh; Katsuyuki Shirai; Masumi Imaeda; Atsushi Musha; Takanori Abe; Masato Shino; Yukihiro Takayasu; Katsumasa Takahashi; Kazuaki Chikamatsu; Takashi Nakano
Journal:  Radiat Oncol       Date:  2017-02-20       Impact factor: 3.481

9.  Radiotherapy for early glottic cancer and salvage surgery after recurrence.

Authors:  Paulo Pontes; Osíris de Oliveira Camponês de Brasil; Francisco de Souza Amorim Filho; Bruno Teixeira de Moraes; Antonio Pontes; José Caporrino Neto
Journal:  Braz J Otorhinolaryngol       Date:  2011-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.